S
Syntonix Pharmaceuticals
A needle-free drug delivery company
About Syntonix Pharmaceuticals
Syntonix Pharmaceuticals, a biopharmaceutical company founded in 1999 by Drs. Richard and Laurence Blumberg, focused on developing novel therapeutic proteins for chronic diseases like hemophilia, anemia, and autoimmune disorders. The company operated from Waltham, Massachusetts, and was centered around its proprietary drug delivery platforms, SynFusion™ and Transceptor™. These technologies were engineered to create long-acting biopharmaceuticals, aiming to reduce the frequency of injections for patients. The Transceptor™ technology utilized a natural pathway to transport antibodies, while the SynFusion™ platform was based on Fc-fusion technology to extend the duration of a drug's effect.
The company's business model revolved around internal development programs and strategic collaborations with other pharmaceutical and biotechnology partners. Syntonix licensed its technologies for the development of various treatments, including therapies for hemophilia B, autoimmune disorders, and enhanced peptide inhalation. One of its key products in development was a long-acting recombinant Factor IX Fc fusion protein (rFIXFc) for treating hemophilia B, which was being co-developed with Biovitrum AB of Sweden. This product had the potential to significantly decrease the number of intravenous injections required for managing the condition. Other collaborations included an agreement with Serono to develop an inhalable Interferon-beta therapy for multiple sclerosis and a partnership with Boehringer Ingelheim to optimize therapeutic peptides for inhalation.
After utilizing angel investments and completing Series A and B funding rounds, which raised a total of $64 million, Syntonix was seeking an additional $80-$100 million in a Series C round in September 2006. During these negotiations, Biogen Idec, a member of the potential venture capital syndicate, expressed interest in an outright acquisition. In January 2007, Biogen Idec announced it would acquire Syntonix Pharmaceuticals. The deal was finalized on February 1, 2007, for an initial payment of $40 million, with potential for up to $80 million more upon reaching certain development milestones, bringing the total potential value to $120 million. Following the acquisition, Syntonix became a wholly-owned subsidiary of Biogen Idec, and its programs, including the promising hemophilia pipeline, were integrated into Biogen's operations.
Source: Dealroom company dataNews
Open roles
Syntonix Pharmaceuticals in the Waltham ecosystem
The Syntonix Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Alta Partners- BCBay City Capital
Pappas Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Syntonix Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Syntonix Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.